104 related articles for article (PubMed ID: 19373038)
1. Toxicity of HIV protease inhibitors: clinical considerations.
Boesecke C; Cooper DA
Curr Opin HIV AIDS; 2008 Nov; 3(6):653-9. PubMed ID: 19373038
[TBL] [Abstract][Full Text] [Related]
2. Protease inhibitor plasma concentrations in HIV antiretroviral therapy.
Justesen US
Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitor therapy in resource-limited settings.
Elliott JH; Pujari S
Curr Opin HIV AIDS; 2008 Nov; 3(6):612-9. PubMed ID: 19373032
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies.
Mallon PW
Curr Opin HIV AIDS; 2007 Jul; 2(4):282-92. PubMed ID: 19372900
[TBL] [Abstract][Full Text] [Related]
5. The management of HIV-1 protease inhibitor pharmacokinetic interactions.
Winston A; Boffito M
J Antimicrob Chemother; 2005 Jul; 56(1):1-5. PubMed ID: 15941777
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy-induced liver alterations.
Walker UA
Curr Opin HIV AIDS; 2007 Jul; 2(4):293-8. PubMed ID: 19372901
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?
Winston A; Khoo S
Curr Opin HIV AIDS; 2008 Nov; 3(6):608-11. PubMed ID: 19373031
[TBL] [Abstract][Full Text] [Related]
8. Resistance to newly approved and investigational protease inhibitors.
De Luca A
Curr Opin HIV AIDS; 2007 Mar; 2(2):130-6. PubMed ID: 19372878
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of HIV protease inhibitors in pregnancy.
van der Lugt J; Colbers A; Burger D
Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
[TBL] [Abstract][Full Text] [Related]
10. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies.
Caron M; Vigouroux C; Bastard JP; Capeau J
Curr Opin HIV AIDS; 2007 Jul; 2(4):268-73. PubMed ID: 19372898
[TBL] [Abstract][Full Text] [Related]
11. Saquinavir, the pioneer antiretroviral protease inhibitor.
la Porte CJ
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
[TBL] [Abstract][Full Text] [Related]
12. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
13. Management of antiretroviral drug toxicity.
Feeney E; Muldoon E; Powderly WG
Curr Opin HIV AIDS; 2006 Sep; 1(5):430-6. PubMed ID: 19372843
[TBL] [Abstract][Full Text] [Related]
14. Approaches to the design of HIV protease inhibitors with improved resistance profiles.
Gulnik SV; Eissenstat M
Curr Opin HIV AIDS; 2008 Nov; 3(6):633-41. PubMed ID: 19373035
[TBL] [Abstract][Full Text] [Related]
15. Initiation of antiretroviral therapy.
Pozniak A
Curr Opin HIV AIDS; 2006 Sep; 1(5):398-408. PubMed ID: 19372839
[TBL] [Abstract][Full Text] [Related]
16. Resistance and viral subtypes: how important are the differences and why do they occur?
Brenner BG
Curr Opin HIV AIDS; 2007 Mar; 2(2):94-102. PubMed ID: 19372873
[TBL] [Abstract][Full Text] [Related]
17. Early treatment of HIV: implications for resource-limited settings.
Hobbs CV; Essajee SM
Curr Opin HIV AIDS; 2009 May; 4(3):222-31. PubMed ID: 19532054
[TBL] [Abstract][Full Text] [Related]
18. Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Struble KA; Chan-Tack KM; Soon GG
Curr Opin HIV AIDS; 2008 Nov; 3(6):676-80. PubMed ID: 19373041
[TBL] [Abstract][Full Text] [Related]
19. Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy.
Hammond E; Nolan D
Curr Opin HIV AIDS; 2007 Jul; 2(4):274-81. PubMed ID: 19372899
[TBL] [Abstract][Full Text] [Related]
20. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.
Blaschke TF
Curr Opin HIV AIDS; 2008 Nov; 3(6):603-7. PubMed ID: 19373030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
